EGFR and non-small cell lung carcinoma: Furthermore, NCT-80 inhibited PD-L1 expression in NSCLC cells that acquired resistance to chemotherapeutic drugs or an EGFR TKI and enhanced the antitumor effects of chemotherapeutic agents.